Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation
| Autor: | Aengus O'Marcaigh, Martina Williams, Matthew Goodyer, Owen P. Smith, Lorna Storey, Melanie Cotter, Niall O'Connell, Mary Gleeson |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Anemia Telomere-Binding Proteins Dyskeratosis Congenita Antibodies Monoclonal Murine-Derived Refractory medicine Humans Immunologic Factors Monoclonal antibody therapy Transplantation biology business.industry Hematopoietic Stem Cell Transplantation Hematopoietic stem cell Mycophenolic Acid medicine.disease medicine.anatomical_structure Treatment Outcome Child Preschool Pediatrics Perinatology and Child Health Immunology Mutation biology.protein Rituximab Anemia Hemolytic Autoimmune Autoimmune hemolytic anemia Antibody business Dyskeratosis congenita Immunosuppressive Agents medicine.drug |
| Zdroj: | Pediatric transplantation. 18(1) |
| ISSN: | 1399-3046 |
| Popis: | AIHA following allogeneic HSCT is appearing more frequently in the literature. It occurs as a result of donor cell-derived antibodies targeting donor red cell antigens. Little guidance exists on the management of such patients, particularly in the pediatric setting. First-line conventional treatment is corticosteroids and/or immunoglobulin therapy with monoclonal antibody therapy reserved for treatment failure. We report our experience of a child refractory to immunoglobulin and steroid therapy who required several infusions of rituximab and immunomodulatory therapy to obtain a clinically significant response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text